GliomaNCT06327048

Application of Cognitive Training Based on the Remind Strategy in Glioma Patients With Cognitive Impairment

A study testing Individual cognitive rehabilitation training based on Remind strategy was given in people with Glioma, run by YuanYuan Ma at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The purpose of this study is to form an interdisciplinary team to dynamically evaluate patient cognitive outcomes and develop an individualized cognitive training program for Chinese brain tumor patients Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Glioma
What is being tested?: Individual cognitive rehabilitation training based on Remind strategy was given
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 69 participants
Where: 1 siteChina
Study dates: 21 Jan 2024to 12 Jan 2025
Phase: Interventional
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Conforming to the diagnostic criteria outlined in the "Chinese Clinical Guidelines for Diagnosis and Treatment of Central Nervous System Gliomas (2015)" ;
Patients diagnosed with brain gliomas through histopathological and/or cytological examination;
MoCA (Montreal Cognitive Assessment) score ≤ 26;
Karnofsky Performance Status (KPS) score ≥ 60, with no history of past illnesses;
Age ≥ 18 years;
Clear consciousness;
Willingness to participate and signed informed consent form.

Who cannot join

Diagnosed with neurological or psychiatric disorders within the past two years;
Impaired consciousness;
Accompanied by severe complications such as infections;
Nursing Delirium Screening Checklist (Nu-DESC) score ≥ 2;
Patients with changes in condition or requiring repeat surgery;
Patients with multiple intracranial tumors;
Inability to effectively complete the questionnaire or withdrawal during the study.

Trial locations and contacts

1 site in 1 country.

China1 site

Yuanyuanma
Lanzhou, Gansu

Other trials in China

About this study

Official title: Application of Cognitive Training Based on Remind Strategy in Glioma Patients With Cognitive Impairment

Read the detailed description

Adult patients diagnosed with glioma who meet the inclusion criteria will be enrolled in this study. Patients admitted to Neurosurgery Ward 1 will be assigned to the intervention group, while those admitted to Neurosurgery Ward 2，ward 3 and Ward 4 will serve as the control group. The intervention group will receive cognitive rehabilitation training based on the Remind strategy in addition to standard rehabilitation care, whereas the control group will receive only standard rehabilitation care. Assessment of patients' cognitive function, quality of life, psychological status, and the effectiveness of cognitive training intervention will be conducted on the first day of admission, before intervention, at the end of the 4-week and 12-week intervention .

Conditions: Glioma
Being tested: Individual cognitive rehabilitation training based on Remind strategy was given
Keywords: cognitive training, cognitive impairment, Quality of Life
Medical subject headings: Glioma, Cognitive Dysfunction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Individual cognitive rehabilitation training based on Remind strategy was givenOther
This training educates and learns patients from the aspects of assessment of cognitive function and strategic compensation for the impact of cognitive impairment on patients, and then conducts attention, memory and executive function training and attention retraining based on patients' cognitive function to improve patients' cognitive function

Study groups in NCT06327048
Study group	Role	What they receive
Control group	No intervention	Routine rehabilitation nursing
Intervention group	Experimental	On the basis of routine rehabilitation nursing, individual cognitive rehabilitation training based on Remind strategy was given Receives: Other: Individual cognitive rehabilitation training based on Remind strategy was given

What is being measured

The primary outcome is the main question the study is designed to answer.

Montreal Cognitive Assessment(MoCA)
The Montreal Cognitive Assessment (MoCA) is commonly used to assess cognitive function, typically taking about 15 minutes to complete. It has a total score of 30 points, with a score of ≥26 considered normal. Lower scores indicate more severe cognitive impairment. MoCA is advantageous due to its ease of administration, short duration, and high reliability and validity.
Measured: The day after admission, 7 days after surgery (baseline), at 4-week and 12-week of intervention.

Secondary outcomes (5)

The European Organization for Research and Treatment of Cancer core Quality of Life Questionnaire (EORTC QLQ-C30)
The European Organization for Research and Treatment of Cancer core Quality of Life Questionnaire (EORTC QLQ-C30) includes five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health and QoL scale, as well as individual items to assess other symptoms commonly experienced by cancer patients (such as dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea), and the perceived economic impact of the disease and treatment. All items are scored using a 4-point Likert scale (1: 'not at all'; to 4: 'very much'), except for two items in the global health/QoL scale which use a modified 7-point linear analog scale. Higher scores indicate poorer quality of life.
Measured: The day after admission, 7 days after surgery (baseline), at 4-week and 12-week of intervention.
The EORTC QLQ-Brain Neoplasms 20(EORTC QLQ-BN20)
The EORTC QLQ-Brain Neoplasms 20(EORTC QLQ-BN20) is a tool specifically designed to assess the quality of life of patients with brain tumors. The instrument consists of four multi-item scales covering: future uncertainty; visual disorders; motor dysfunction; communication deficit. Additionally, seven individual items assess headache, seizures, drowsiness, hair loss, itching, weakness of legs, and bladder control. All items and scores are evaluated on a scale of 0-100, with higher scores reflecting more severe symptoms.
Measured: The day after admission, 7 days after surgery (baseline), at 4-week and 12-week of intervention.
Self-Rating Anxiety Scale(SAS)
The Self-Rating Anxiety Scale (SAS) is used to assess the subjective feelings of anxiety patients. The scale consists of 20 items aimed at quantifying the severity of anxiety-related symptoms experienced by patients. It is divided into four levels on a Likert four-point scale: None or rarely, Sometimes, Often, and Always. Scores range from 20 to 80, with 20-44 considered normal, 45-59 indicating mild to moderate anxiety levels, 60-74 indicating severe anxiety levels, and extreme anxiety levels falling between 75 and 80.
Measured: The day after admission, 7 days after surgery (baseline), at 4-week and 12-week of intervention.
Self-Rating Depression Scale(SDS)
The Self-Rating Depression Scale (SDS) is used to assess an individual's subjective feelings of depression. The scale consists of 20 items rated on a Likert four-point scale: None or rarely, Sometimes, Often, and Always. Higher scores indicate higher levels of depression in the individual.
Measured: The day after admission, 7 days after surgery (baseline), at 4-week and 12-week of intervention.
Modified Barthel Index(MBI)
The Modified Barthel Index (MBI) is widely used in clinical practice to assess activities of daily living (ADL). It reflects patients' ability to perform self-care activities such as dressing, feeding, personal hygiene, as well as mobility activities such as sitting, standing, and walking. This scale is straightforward, easy to administer, and has good reliability and validity.
Measured: The day after admission, 7 days after surgery (baseline), at 4-week and 12-week of intervention.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

21 Jan 202412 Jan 2025

First posted25 Mar 2024
Study start21 Jan 2024
Primary completion12 Jan 2025
Study completion12 Jan 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (1)Papers the sponsor has linked to this study.
Other trials for GliomaStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Other
Allocation: Non-randomised
Intervention model: Parallel groups
Model description: Non-randomized intervention study
Masking: Single blind
Who is masked: Outcomes assessor
Enrolment: 69 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06327048
Sponsor's protocol ID: LZUHLXY20230110
Status last verified: Oct 2024
First submitted: 29 Feb 2024
Last updated: 12 Aug 2025
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No: The research data is being preserved by the research team and will be presented in the published paper after the study is completed.

Publications

Ma Y, Zhou R, Ma Y, Mou C, He B, Sun D, Wu X, Dai Y, Ma P. Application of multidimensional cognitive training in the early postoperative period for glioma patients with cognitive impairment. J Neurooncol. 2026 Apr 27;177(3):128. doi: 10.1007/s11060-026-05575-7.
PubMed 42043588

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Active, not recruitingPhase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
RecruitingPhase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Low Grade Astrocytoma, Low Grade Glioma
RecruitingPhase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma

All Glioma trials

Study at a glance

From the registry record, last updated by the sponsor on 12 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Application of Cognitive Training Based on Remind Strategy in Glioma Patients With Cognitive Impairment
ClinicalTrials.gov ID: NCT06327048
Acronym / sponsor ID: LZUHLXY20230110
Conditions: Glioma
Keywords: cognitive training, cognitive impairment, Quality of Life
Study type: Interventional
Recruitment status: Completed
Enrolment: 69 participants (actual)
Lead sponsor: YuanYuan MaUniversity, hospital or other
Study start: 21 Jan 2024 (actual)
Primary completion: 12 Jan 2025 (actual)
Study completion: 12 Jan 2025 (actual)
First posted: 25 Mar 2024 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Other
Allocation: Non-randomised
Intervention model: Parallel groups
Masking: Single blind (outcomes assessor)
Number of arms: 2
Model description: Non-randomized intervention study

Arm	Type	Receives
Control group	No intervention	–Routine rehabilitation nursing
Intervention group	Experimental	Other: Individual cognitive rehabilitation training based on Remind strategy was givenOn the basis of routine rehabilitation nursing, individual cognitive rehabilitation training based on Remind strategy was given

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (7 listed)

Conforming to the diagnostic criteria outlined in the "Chinese Clinical Guidelines for Diagnosis and Treatment of Central Nervous System Gliomas (2015)" ;
Patients diagnosed with brain gliomas through histopathological and/or cytological examination;
MoCA (Montreal Cognitive Assessment) score ≤ 26;
Karnofsky Performance Status (KPS) score ≥ 60, with no history of past illnesses;
Age ≥ 18 years;

Key exclusion criteria (7 listed)

Diagnosed with neurological or psychiatric disorders within the past two years;
Impaired consciousness;
Accompanied by severe complications such as infections;
Nursing Delirium Screening Checklist (Nu-DESC) score ≥ 2;
Patients with changes in condition or requiring repeat surgery;

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Individual cognitive rehabilitation training based on Remind strategy was givenThis training educates and learns patients from the aspects of assessment of cognitive function and strategic compensation for the impact of cognitive impairment on patients, and then conducts attention, memory and executive function training and attention retraining based on patients' cognitive function to improve patients' cognitive function	Other	Intervention group

Primary outcome

Montreal Cognitive Assessment(MoCA)
Time frame: The day after admission, 7 days after surgery (baseline), at 4-week and 12-week of intervention.
The Montreal Cognitive Assessment (MoCA) is commonly used to assess cognitive function, typically taking about 15 minutes to complete. It has a total score of 30 points, with a score of ≥26 considered normal. Lower scores indicate more severe cognitive impairment. MoCA is advantageous due to its ease of administration, short duration, and high reliability and validity.

5 secondary outcomes

The European Organization for Research and Treatment of Cancer core Quality of Life Questionnaire (EORTC QLQ-C30)
Time frame: The day after admission, 7 days after surgery (baseline), at 4-week and 12-week of intervention.
The EORTC QLQ-Brain Neoplasms 20(EORTC QLQ-BN20)
Time frame: The day after admission, 7 days after surgery (baseline), at 4-week and 12-week of intervention.
Self-Rating Anxiety Scale(SAS)
Time frame: The day after admission, 7 days after surgery (baseline), at 4-week and 12-week of intervention.
Self-Rating Depression Scale(SDS)
Time frame: The day after admission, 7 days after surgery (baseline), at 4-week and 12-week of intervention.
Modified Barthel Index(MBI)
Time frame: The day after admission, 7 days after surgery (baseline), at 4-week and 12-week of intervention.

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 12 Aug 2025.
Derived from this study: PubMed 42043588Ma Y, Zhou R, Ma Y, Mou C, He B, Sun D, Wu X, Dai Y, Ma P. Application of multidimensional cognitive training in the early postoperative period for glioma patients with cognitive impairment. J Neurooncol. 2026 Apr 27;177(3):128. doi: 10.1007/s11060-026-05575-7.
Individual participant dataSharing planned: No. The research data is being preserved by the research team and will be presented in the published paper after the study is completed.

Related trials for Glioma

Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Active, not recruitingPhase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
RecruitingPhase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Low Grade Astrocytoma, Low Grade Glioma
RecruitingPhase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

peifen ma, Master study director

Lanzhou University Second Hospital

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing Individual cognitive rehabilitation training based on Remind strategy was given in people with Glioma, run by YuanYuan Ma at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Montreal Cognitive Assessment(MoCA) (time frame: The day after admission, 7 days after surgery (baseline), at 4-week and 12-week of intervention.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06327048, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2025.